AstraZeneca is a global pharmaceutical company that employs over 70,000 people; more than 3,100 of them with PhDs. The firm’s purpose is to push the boundaries of science to deliver life-changing medicines. This is focused on enhanced innovation and the sustainable delivery of life-changing medicines that improve patient outcomes and health experience.
Staggering Challenges over multiple stages, such as a Theoretical Challenge followed by a Reduction to Practice (RTP) Challenge, can have a number of benefits including helping to inform the viability and direction of the final solution requirements, incentivizing Solver participation by reducing risk, and allowing for more advanced deliverables.
This is an approach AstraZeneca has employed twice in recent Challenges; both occasions involved a Theoretical Challenge, requiring Solvers to submit only a written proposal, followed by an RTP Challenge.